Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Operating Leases (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Operating Leases for 7 consecutive years, with $139.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 5.54% to $139.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $139.8 million, a 5.54% decrease, with the full-year FY2025 number at $139.8 million, down 5.54% from a year prior.
  • Operating Leases was $139.8 million for Q4 2025 at Beam Therapeutics, up from $138.7 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $168.6 million in Q4 2022 to a low of $125.8 million in Q1 2021.
  • A 5-year average of $149.0 million and a median of $148.5 million in 2024 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: skyrocketed 459.09% in 2021, then decreased 7.48% in 2024.
  • Beam Therapeutics' Operating Leases stood at $134.8 million in 2021, then grew by 25.08% to $168.6 million in 2022, then fell by 5.17% to $159.9 million in 2023, then dropped by 7.48% to $148.0 million in 2024, then fell by 5.54% to $139.8 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Operating Leases are $139.8 million (Q4 2025), $138.7 million (Q3 2025), and $141.9 million (Q2 2025).